By Fineline Cube Beijing Sinotau International Pharmaceutical Technology Co., Ltd., a specialized nuclear medicine enterprise, announced that the National Medical Products Administration (NMPA) has accepted for review its New Drug Application (NDA) for XTR020 (flotufolastat F-18 gallium), a radiopharmaceutical diagnostic agent for prostate cancer detection.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Application Type | New Drug Application (NDA) |
| Product | XTR020 (flotufolastat F-18 gallium) |
| Indication | Detection of biochemical recurrence (BCR) of prostate cancer following prior treatment |
| Submission Basis | China Phase III clinical study data |
| Review Status | Accepted for formal review |
Clinical Evidence – Phase III Trial
The NDA filing leveraged results from a China-based Phase III clinical study that demonstrated compelling diagnostic performance:
- Primary Endpoint: Met prespecified target for correct detection rate (CDR) at the individual patient level
- Diagnostic Performance: High accuracy in detecting biochemical recurrence (BCR) of prostate cancer post-treatment
- Safety Profile: No serious adverse reactions reported across the study population
- Protocol Completion: 100% of patients successfully completed the study protocol, confirming favorable tolerability
The trial specifically evaluated XTR020’s ability to accurately identify prostate cancer recurrence in patients who had previously undergone treatment, addressing a critical unmet need in post-treatment monitoring.
Product Profile & Market Positioning
- Molecule: Flotufolastat F-18 gallium (XTR020)
- Therapeutic Area: Nuclear medicine / Radiopharmaceutical diagnostics
- Target Population: Prostate cancer patients with suspected biochemical recurrence following initial treatment
- Technology Platform: F-18 labeled radiopharmaceutical for PET imaging
- Competitive Landscape: Part of growing precision oncology diagnostic market in China
Strategic Implications
- Market Opportunity: China represents one of the world’s largest prostate cancer markets with increasing demand for advanced diagnostic tools
- Regulatory Pathway: NMPA acceptance marks a significant milestone toward potential commercialization in the Chinese market
- Healthcare Impact: Accurate detection of biochemical recurrence enables earlier intervention and improved patient outcomes
- Company Positioning: Success would establish Beijing Sinotau as a key player in China’s nuclear medicine sector
Industry Outlook
The acceptance of XTR020’s NDA reflects China’s growing emphasis on advanced diagnostic capabilities in oncology care. With prostate cancer incidence rising in China and increasing focus on precision medicine, radiopharmaceuticals like XTR020 represent a strategic growth area for domestic pharmaceutical companies.
If approved, XTR020 would provide Chinese clinicians with a domestically developed, high-performance diagnostic tool for managing prostate cancer patients post-treatment, potentially reducing reliance on imported alternatives.
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory review timelines, clinical outcomes, and commercial expectations for XTR020. Actual results may differ due to risks including final regulatory decisions, market adoption, and competitive dynamics in China’s nuclear medicine sector.-Fineline Info & Tech